SPION-Decorated Exosome Delivered BAY55-9837 Targeting the Pancreas through Magnetism to Improve the Blood GLC Response.

BAY55-9837, a potential therapeutic peptide in the treatment of type 2 diabetes mellitus (T2DM), is capable of inducing glucose (GLC)-dependent insulin secretion. However, the therapeutic benefit of BAY55-9837 is limited by its short half-life, lack of targeting ability, and poor blood GLC response. How to improve the blood GLC response of BAY55-9837 is an existing problem that needs to be solved. In this study, a method for preparing BAY55-9837-loaded exosomes coupled with superparamagnetic iron oxide nanoparticle (SPIONs) with pancreas islet targeting activity and an enhanced blood GLC response with the help of an external magnetic force (MF) is demonstrated. The plasma half-life of BAY55-9837 loaded in exosome-SPION is 27-fold longer than that of BAY55-9837. The active targeting property of SIPONs enables BAY-exosomes to gain a favorable targeting property, which improves the BAY55-9837 blood GLC response capacity with the help of an external MF. In vivo studies show that BAY-loaded exosome-based vehicle delivery enhances pancreas islet targeting under an external MF and markedly increases insulin secretion, thereby leading to the alleviation of hyperglycemia. The chronic administration of BAY-exosome-SPION/MF significantly improves glycosylated hemoglobin and lipid profiles. BAY-exosome-SPION/MF maybe a promising candidate for a peptide drug carrier for T2DM with a better blood GLC response.

[1]  Chih-Kuang Yeh,et al.  Ultrasound/Magnetic Targeting with SPIO-DOX-Microbubble Complex for Image-Guided Drug Delivery in Brain Tumors , 2016, Theranostics.

[2]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[3]  Hong Ding,et al.  Image Guided Biodistribution of Drugs and Drug Delivery , 2012, Theranostics.

[4]  D. Huo,et al.  Investigation on clotting and hemolysis characteristics of heparin-immobilized polyether sulfones biomembrane. , 2008, Journal of biomedical materials research. Part A.

[5]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[6]  F. Brunicardi,et al.  Islet Vasculature as a Regulator of Endocrine Pancreas Function , 2007, World Journal of Surgery.

[7]  G. Rutter,et al.  Overexpression of lactate dehydrogenase A attenuates glucose‐induced insulin secretion in stable MIN‐6 β‐cell lines , 1998, FEBS letters.

[8]  I. Farooqi,et al.  A New Drug Target for Type 2 Diabetes , 2017, Cell.

[9]  A. Smith,et al.  Glycosylated hemoglobin and its temporal relationship to plasma glucose in non-insulin dependent (type 2) diabetes mellitus. , 1982, Metabolism: Clinical and Experimental.

[10]  Gang Bao,et al.  Magnetic nanoparticle probes , 2005 .

[11]  M. Wood,et al.  Exosome nanotechnology: An emerging paradigm shift in drug delivery , 2011, BioEssays : news and reviews in molecular, cellular and developmental biology.

[12]  H. Kaneto,et al.  Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes , 2005, Journal of Molecular Medicine.

[13]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[14]  Peter G Maxim,et al.  Particle size, magnetic field, and blood velocity effects on particle retention in magnetic drug targeting. , 2009, Medical physics.

[15]  R. DeFronzo.  The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM , 1988, Diabetes.

[16]  Min Ma,et al.  A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions. , 2015, Biomaterials.

[17]  Jian Song,et al.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.

[18]  Song Fan,et al.  Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. , 2018, Biomaterials.

[19]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. , 2018, Diabetes research and clinical practice.

[20]  L. Wu,et al.  Hydrogen sulfide-induced inhibition of L-type Ca2+ channels and insulin secretion in mouse pancreatic beta cells , 2013, Diabetologia.

[21]  A. Seifalian,et al.  Exosomes as nano-theranostic delivery platforms for gene therapy. , 2013, Advanced drug delivery reviews.

[22]  C. Pan,et al.  Engineering Novel VPAC2-Selective Agonists with Improved Stability and Glucose-Lowering Activity in Vivo , 2007, Journal of Pharmacology and Experimental Therapeutics.

[23]  Sumit Arora,et al.  Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers , 2012, International journal of nanomedicine.

[24]  Myung Soo Kim,et al.  Using exosomes, naturally-equipped nanocarriers, for drug delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[25]  M. Moniatte,et al.  Surface charge of polymer coated SPIONs influences the serum protein adsorption, colloidal stability and subsequent cell interaction in vitro. , 2013, Nanoscale.

[26]  Franz Hofmann,et al.  Unchanged β-Adrenergic Stimulation of Cardiac L-type Calcium Channels in Cav1.2 Phosphorylation Site S1928A Mutant Mice* , 2008, Journal of Biological Chemistry.

[27]  C. Pan,et al.  Generation of Highly Selective VPAC2 Receptor Agonists by High Throughput Mutagenesis of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Peptide* , 2003, The Journal of Biological Chemistry.

[28]  Lionel Blanc,et al.  Exosome release by reticulocytes--an integral part of the red blood cell differentiation system. , 2005, Blood cells, molecules & diseases.

[29]  Mutsa P. Seremwe,et al.  A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents , 2017, PloS one.

[30]  S. Lim,et al.  Exosomes for drug delivery - a novel application for the mesenchymal stem cell. , 2013, Biotechnology advances.

[31]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[32]  Chihchen Chen,et al.  Paper-Based for Isolation of Extracellular Vesicles. , 2017, Methods in molecular biology.

[33]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[34]  Xin Hou,et al.  Blood Exosomes Endowed with Magnetic and Targeting Properties for Cancer Therapy. , 2016, ACS nano.

[35]  B. Pakkenberg,et al.  Genetic background determines the size and structure of the endocrine pancreas. , 2005, Diabetes.

[36]  I. Ali,et al.  Synthesis, DNA binding, hemolysis assays and anticancer studies of copper(II), nickel(II) and iron(III) complexes of a pyrazoline-based ligand. , 2013, Future medicinal chemistry.

[37]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.

[38]  B. Ahrén,et al.  Role of VIP and PACAP in islet function , 2007, Peptides.

[39]  Zhiqiang Gao,et al.  Progress in Exosome Isolation Techniques , 2017, Theranostics.

[40]  T. Pozzan,et al.  Ca2+ Depletion from Granules Inhibits Exocytosis , 1998, The Journal of Biological Chemistry.

[41]  D. Moller,et al.  New drug targets for type 2 diabetes and the metabolic syndrome , 2001, Nature.

[42]  P. Leung,et al.  The Potential Protective Action of Vitamin D in Hepatic Insulin Resistance and Pancreatic Islet Dysfunction in Type 2 Diabetes Mellitus , 2016, Nutrients.

[43]  P. Zimmet,et al.  The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives , 2012, Nature Reviews Endocrinology.

[44]  C. Pan,et al.  A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. , 2002, Diabetes.

[45]  Patrik Rorsman,et al.  Glucose-sensing mechanisms in pancreatic β-cells , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.

[46]  R. Fernández-Lafuente,et al.  Preparation of activated supports containing low pK amino groups. A new tool for protein immobilization via the carboxyl coupling method. , 1993, Enzyme and microbial technology.

[47]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[48]  Q. Tang,et al.  NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. , 2018, Biomaterials.

[49]  L. Missiaen,et al.  mTOR-Controlled Autophagy Requires Intracellular Ca2+ Signaling , 2013, PloS one.

[50]  C. Claussen,et al.  Transferrin receptor upregulation: in vitro labeling of rat mesenchymal stem cells with superparamagnetic iron oxide. , 2007, Radiology.

[51]  Rajesh Singh,et al.  Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.

[52]  J. Bockaert,et al.  Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat , 1996, British journal of pharmacology.

[53]  F. Zhang,et al.  Rational synthesis of magnetic thermosensitive microcontainers as targeting drug carriers. , 2009, Small.

[54]  Yanbo Zhang,et al.  Mesenchymal Stem Cells for Regenerative Medicine , 2019, Cells.

[55]  A. Simchi,et al.  Size-controlled synthesis of superparamagnetic iron oxide nanoparticles and their surface coating by gold for biomedical applications , 2012 .

[56]  P. Robberecht,et al.  The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP2 Receptor Subclass , 1997, Peptides.

[57]  P. MacDonald,et al.  Rp-cAMPS Prodrugs Reveal the cAMP Dependence of First-Phase Glucose-Stimulated Insulin Secretion. , 2015, Molecular endocrinology.